Farrell Healion is the Head of Emerging Technologies at AstraZeneca, where he spearheads the operational readiness and strategy for integrating new technologies into clinical trials. With 13 years of experience, has a proven track record in driving growth, innovation and transformation in Digital Health Technologies, from both supplier and sponsor perspectives. Farrell is passionate about human-centred, value-driven solutions with a focus on patient-centric and site-centric approaches. His award-winning thought leadership is evident through roles in industry groups like the Decentralized Trials & Research Alliance (DTRA) and as Co-Chair of the C-Path eCOA Consortium’s PRO Consortium.

Dr. Faith Matcham is a Health Psychologist and Associate Professor of Psychology at the University of Sussex. Her research focuses on the intricate relationship between mental and physical health, exploring how psychological factors influence the management and outcomes of chronic illnesses. She has a particular interest in leveraging digital technologies to enhance the assessment, monitoring, and treatment of long-term conditions. By integrating innovative digital tools into healthcare, Dr. Matcham aims to improve patient outcomes, promote early intervention, and bridge the gap between mental and physical health care. Her work contributes to the evolving landscape of digital health and personalised medicine.

Julien is passionate about digital transformation, innovation and Digital Health; a geeky intrapreneur to make it short! After years of various leadership roles at both local and international level (such as European Customer Analytics Team Leader, Head of Operations Switzerland or National Sales Manager) and two years in Germany leading the Analytics Transformation for the German Hub (Germany, Austria and Switzerland), he is now back to his native Switzerland, first as International Digital Health & Innovation Sr Director with Eli Lilly International Business Unit and currently as Sr Director International Patient Success and Innovation as part of our Global Team.

As the Clinical Digital Health & Innovation Lead at Global Clinical Development, Dr. Eva Topole leverages her clinical expertise in respiratory medicine and deep understanding of clinical development and digital health innovation to drive advancements. She leads collaborative initiatives with R&D teams to integrate digital health solutions and novel data strategies, optimizing clinical trials, enhancing patient experiences, and generating valuable research insights. Dr. Topole works closely with clinical teams across therapeutic areas to implement innovative approaches. Her background includes roles as Senior Consultant in Respiratory Medicine and head of the Functional Respiratory Diagnostic Department. Known for her visionary leadership, she cultivates strategic partnerships to stay at the forefront of digital health trends.

Alice Biggane is an Acting Associate Director in Outcomes Innovation at Pfizer UK. In this role, Alice works across multiple disease areas and assets, identifying and bridging any evidence gaps that exist in terms of health-related quality of life and utility values for HTA and access. Alice has a range of academic and industry experience, all focused on methodological efforts around enhancing patient centeredness in drug development and market access.

RWE and outcomes researcher with experience supporting the pharmaceutical industry in their patient-focused approaches and evidence generation for pre and post launch activities. OPEL (Otsuka Pharmaceutical Europe Limited) is the European holding company of Otsuka Pharmaceuticals and established in 1979.

Vivienne is a patient experience and outcomes researcher at Modus Outcomes, UK team. In this role she partnerships with a broad range of clients to design bespoke PCO strategies to accumulate evidence to successfully meet clinical development goals and beyond. With a trial methodology and HCP background, Vivienne is particularly interested in prioritising patient/participant involvement in clinical research from the very beginning.

Jill is a Professor in Health Outcomes Research at the University of Sheffield and is a core member of the SCHARR Outcomes group. Her research focuses on the development, refinement, and evaluation of PROMs in different health conditions using a mixed methods whilst keeping the patient at the centre of the approach. She has experience in developing a number of condition-specific instruments, and expertise in research with children, mental health and rare progressive life-limiting conditions. She has presented at national and international conferences and has published widely in high quality clinical and methodological journals.

Hannah is the Director of Medical Information, Europe at ProPharma, where she leads dedicated client services across the continent. With 16 years of experience in Medical Information (MI), Hannah has supported pharmaceutical companies globally. She is passionate about the evolution of MI to better meet the needs of customers and clients. At ProPharma, we help pharmaceutical, biotechnology, and medical device companies bring life-changing therapies to market. Our mission is simple – improving patient health and safety by delivering the highest quality regulatory, compliance, clinical research, pharmacovigilance, and medical information services throughout the entire product lifecycle.

Stefne has more than 20 years’ experience in the Pharmaceutical Industry in Medical Affairs, Pharmacovigilance and Medical Information. She currently holds the role of Medical Information and Review Lead for International Markets at Pfizer and serves as the MILE (Medical Information Leaders in Europe) President. Stefne is a change champion that has led various change initiatives both within her company and in her MILE Leadership position.

Robyn Rennick has extensive international pharmaceutical industry experience, with over 20 years in medical information, medical affairs, quality and scientific communications roles. Quality, compliance and risk are areas of key interest.

Julian De Gabriele is a registered pharmacist with the General Pharmaceutical Council (GPhC) and has over 15 years of experience in the pharmaceutical industry. As Head of Global Medical Information & Content Management at Viatris, he leads global teams in delivering high-quality, compliant medical information. With a background in sales, medical affairs, and compliance, Julian brings a comprehensive perspective to the evolving medical information landscape. Viatris is a global healthcare company committed to empowering people worldwide through access to high-quality medicines. Julian’s expertise in optimizing operations and driving strategic initiatives has contributed to advancing medical information services across international markets.

Michelle is currently the Head of Global Medical Information at Recordati Rare Diseases and Vice President of the pan-pharmaceutical organization Medical Information Leaders in Europe (MILE). She has worked in a variety of roles within medical affairs in both pharma and biotech. She is an accomplished and success-oriented senior leader with extensive international experience operationalizing and digitally transforming many aspects of medical/scientific affairs and customer engagement. She has also recently become the Chief Operating Officer of Unbiased Science (a Vital Statistics Consulting company) a multi-media, health communications organization that brings credible scientific information to over 500K followers worldwide. She is a driver for and enthusiastic about the value of using technology and AI to enable and drive businesses, to achieve better reach & impact in healthcare & health communications, and to improve customer experience.

Senior international Pharma executive with 25 years industry experience in Medical Affairs and Clinical Development roles in top 10 global Life Sciences companies. Currently Director European Medical Affairs HEOR and Patient Access for Uniphar, a Global Healthcare Service Provider. At Uniphar we specialise in supporting Biotechnology companies strategically plan for and then execute their product Launches and Commercial Roll-out across Europe We have extensive expertise in preparation of launch of innovative products for Infectious Disease, Rare Diseases and Neurology therapies.

Over the last decade, Sophie has worked across several Medical Affairs functions, including head office and field roles located within local affiliates and across regional/global territories. Her focus in the last five years has been Field Medical as both an MSL and within Field Excellence. In addition to this, Sophie holds a Board Position for the London Chapter of the Health Care Business Women’s Association as Director at Large Communications and Marketing.

Lana holds a PhD in Neurosciences from the University of Geneva and both an MSc and BSc from the University of Zurich. She completed Advanced Studies in Big Data and AI at the University of St. Gallen and is continues her professional education with MIT. In her current role, Lana is actively involved in implementation of AI and digital innovation at Novartis in Global Medical Affairs. Lana has been with Novartis since 2014 and has previously held roles in Regulatory Affairs, gaining experience working in global roles and in a country organization. She has been driving collaborative AI initiatives using ML and NLP, established a data quality governance framework, and optimized data pipelines for analytics. Outside of work, Lana enjoys hiking, including climbing Mount Fuji, and traveling. To date, she has visited every continent except Antarctica. She also enjoys reading, focusing on self-development, and spending time with her family.

Dr. David Gillen has been CMO for Norgine since 2022. Prior to this role, he trained in Medicine at St Mary’s Hospital London and qualified in 1992. After Postgrad training in the NHS, Dr. Gillen worked at Pfizer in R&D and Med Affairs from 1999 -2010. Following that, he had senior positions in Gilead, Celgene and Vertex.

A biologist by trade, I have spent more than 20 years in the pharmaceutical industry in various regulatory and leaderships roles. Having worked in small and medium size companies, I have supported the QA, Supply Chain and artwork teams from a regulatory perspective. I now lead the CMC Regulatory Scientists team responsible for the development products of a large pharma company.

After obtaining her MSc in Biomedicine, Irene began her career in various science and health communication roles at non-profit organizations. She then transitioned to Regulatory Affairs, where she worked for 14 years as a local and EU Regulatory Manager at the Dutch Bayer affiliate, supporting various therapeutic areas. In 2023, she took on her current role in global labeling, where she leads initiatives on patient-friendly labeling and the implementation of AI in Regulatory Affairs. Irene is passionate about improving healthcare communication and leveraging technology to enhance regulatory processes.

Dr. Jessica Santos is the Global Compliance and Quality Director and Data Protection Officer in Oracle Life Sciences, provides consulting and research to communicate the value and potential for products and services that fall under healthcare regulation and legislation. Jessica provides oversight and support across global offices in regulation, ethics and compliance, and responsible for maintaining, anticipating and coordinating all activities regarding compliance, privacy, ethics and quality framework on clinical, real world and market research.

Megann Looker (BA Hons) is Head of Global Product Labelling at Jazz Pharmaceuticals. Over 23 years, Megann has held key roles: previously lead for Regulatory Labeling EMEA at Celgene, and prior, Regulatory Strategy at Wyeth, and Apotex. She has served as a KOL member of LabelNet for over 14 years, and has held membership of ePI and IDMP Task Forces across Europe. Jazz is a midsized biotech with a focus on oncology and neuroscience, boldly taking on challenging, complex diseases and introducing new, transformative therapeutic solutions.

Sheila is a global leader in patient engagement, known for driving impactful, multi-stakeholder collaborations that elevate the patient voice in healthcare. With over a decade of experience, she has shaped international advocacy efforts, advised on patient-centered research, and influenced industry best practices. She serves on the Board of PiCC United as the Community Manager, supporting underrepresented patient organizations, and currently contributes to EURORDIS’ Mental Health and Wellbeing project. A former WAPO Board Member, she has engaged with regulators, pharma, and policymakers to co-create meaningful change. An EUPATI Fellow and sought-after speaker, Sheila is recognized for her strategic vision and commitment to patient-centered innovation.

Pauline Frank has worked 17 years in the pharmaceutical industry across a variety of roles to enable functional excellence in support of bringing innovative medicines faster and responsibly to patients. She has led global initiatives in medical information and communications, technology platforms and digital solutions, healthcare professional and patient engagement. As a Strategic Connector at Patient Co-Next, Pauline provides independent strategic advice on the status and implementation of patient engagement and patient centricity in the healthcare industry, reflecting reality without bias. Areas of expertise includes clinical trials, experience research, inclusivity, health tech, and more.

As Managing Director Europe, Tobias is responsible for SubjectWell’s Europe division. As a scientific researcher, Tobias experienced the problem to recruit patients for a clinical trial himself, so he founded and built Trials24 into one of Europe’s leading patient recruitment companies. Trials24 joined forces with SubjectWell in September 2024. At SubjectWell, our mission is to improve global healthcare. We do this by providing the industry’s most accurate, diverse, predictable, patient-centric technology platform, that connects patients and caregivers to breakthrough healthcare opportunities.

Rasmus Hjorth has several years of experience working with patient engagement in clinical research for the patient recruitment company, James Lind Care. His work centers around engaging patients in clinical trials which includes connecting patients with clinical research projects, developing services and communication that increase the awareness and interest about clinical research among patients. He also has years of experience developing advertisement- and information material for recruiting patients to clinical trials. Rasmus holds a Master’s degree in communication and besides his job as Head of Communication in James Lind Care he is a member of the board in the Danish Lung Patient Association.

Carole Sian Scrafton, Ba (Hons) MBS (dist.) Director / Co-Founder of Flutters and Strutters Patient Advocacy Flutters and Strutters Patient Advocacy Organisation for chronic / rare illnesses, a patient-driven and focused patient advocacy organisation that is for everyone #notjustpatients. Carole is a patient with multiple chronic illnesses and a genetic connective tissue disorder, two rare gene mutations, and rare bone anomalies. On top of all that has been under treatment for Non-Small Cell Lung Cancer. Connecting different stakeholders from across the medical, clinical, healthcare industries, including digital health, pharma, research and development. With her organisation is helping to develop, nurture and advocate for multidisciplinary / multi-stakeholder approaches to all aspects of medical healthcare so that chronic illness & rare disease patients can receive the type of care and treatments that they need. Supporting disease education and awareness through better medical and health communications. Actively working on patient engagement projects collaboratively with multi-stakeholder teams with Patient Focused Medicine Development, and other projects within the rare disease research and expanded access spaces. Carole is a patient speaker, author, and reviewer. Campaigns and advocates at many levels including patient forums, as well as taking part in many global conferences, in person or via the internet. She encourages more efficient patient engagement practises with a view to the better development of therapies and treatments within the pharma, medical, and clinical environments.

Chiara Castellarin is an Associate Brand Director at Eisai EMEA, a global company specialising in oncology and embodying an ethos of putting patients and their families first. Drawing on her experience as a Pharmacist and Marketeer, she blends her clinical expertise and strategic thinking to to drive innovative, patient-centered initiatives. Committed to growing both professionally and personally, she remains actively involved in the patient and healthcare community.

Steve is a Patient Advocate, Patient Engagement Consultant and Pharma Business Consultant bringing a unique breadth of experience from personal lived experience with stage 4 cancer, aggregated insights from thousands of patients, and a 40-year career in pharma management and the NHS
As a Patient Engagement Consultant, Steve brings a true understanding of the requirements of patients, pharma and HCPs, together with guidance on partnering with and interpreting between multiple stakeholders
As a Patient Advocate, Steve runs the StriveForFive.org campaign top bring hope in stage 4 cancer, provides individual patient advice and support, advocates for improved health care, and delivers presentations and publications.

Flo is an expert eCOA scientist who has spent her career advising and guiding organizations on the electronic capture of clinical outcome assessments (COA) and the use of digital health technologies (DHTs) in clinical trials. uMotif is a modern eCOA and eConsent platform powering clinical and real-world research. At uMotif, Flo provides Scientific Leadership across the organization, ensuring that the scientific voice is embedded across all functional areas to inform rigorous scientific practices.

Chelsea has over a decade of experience in the pharmaceutical industry, working in patient engagement across various disease areas such as HIV, liver disease, women’s health, and rare diseases. She is passionate about building strong, trusting relationships with the community to elevate the voices of patients and caregivers throughout the medicines’ development lifecycle. Chelsea enjoys working with cross-functional teams to inform and shape evidence-based strategies and tactics, delivered in partnership with the community and colleagues.

Alan Thomas is a patient engagement advocate for rare diseases in general and Ataxia in particular. As a patient with a ‘life-limiting’ rare disease, he can convey the patient engagement message from his point of view in all issues regarding the wellbeing of patients. Alan has established a patient-driven and focused charity (www.ataxia-and-me.org) and campaigns at many levels, including patient forums, local and regional health boards, Welsh/UK government organisations, as well as taking part in many global conferences, in person or via the internet.